We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
BYDUREON (AstraZeneca Pty Ltd)
Product name
BYDUREON
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
253 working days (255)
Active ingredients
exenatide
Registration type
EOI
Indication
BYDUREON (once weekly injection) is now also indicated for the treatment of type 2 diabetes mellitus to improve glycaemic control in combination with basal insulin, with or without metformin.